This is the hover veil
Do you have a clinical question?
About the taskforce
About the guidelines
About the taskforce
About the guidelines
Aboriginal and Torres Strait Islander people
Acute and Critical Care Panel
Allied Health Professions Australia
Angiotensin 2 receptor agonist (C21)
ANZPID COVID-19 Clinical Reference Group
Australasian Sleep Association
Australia Day honours
Australian and New Zealand Society for Geriatric Medicine
Australian College of Midwives
Australian Commission on Safety and Quality in Health Care
Australian Living Evidence Consortium (ALEC)
Bamlanivimab plus etesevimab
Basic Life Support
Cardiac Arrest Working Group
Care after COVID-19
Care after COVID-19 flowchart
Care of Children
Care of Older People and Palliative Care Panel
Casirivimab plus imdevimab (Ronapreve)
Children and adolescents
Critical Disease Panel
CT-P59 monoclonal antibody
Definitions of disease severity
Delayed umbilical cord clamping
Expert Advisory Group
Extracorporeal membrane oxygenation
Global Commission on Evidence
Guideline Leadership Group
High-flow nasal oxygen
Hospital and Acute Care Panel
Hydroxychloroquine plus azithromycin
Ian Potter Foundation
Immunodulatory treatments table
Immunoglobulin plus methylprednisolone
Infection Control Matters Podcast
Infection Prevention and Control (IPC) Panel
Interferon β-1a (inhaled)
International Women's Day
Management of cardiac arrest
Monoclonal antibody therapy
New England Journal of Medicine
New Topics & Questions
Nirmatrelvir plus ritonavir (Paxlovid)
Observational Data Working Group
Oestrogen containing therapies
Paediatric & Adolescent Care
Paediatric & Adolescent Care Panel
Paediatric and Adolescent Care
Paediatric Decision Tool
Palliative and Aged Care Panel
Palliative Care Working Group
Pathways to Care
Paxlovid prescribing guide
Personal Protective Equipment (PPE)
Pregnancy and perinatal care
Pregnancy and Perinatal Panel
Pregnant & Postpartum women
Pregnant or breastfeeding women
Primary and Chronic Care Panel
Risk classification tool
Royal Australian College of Surgeons
Rural and remote care
Senior Clinical Fellow
Senior Evidence Officer
Sofosbuvir plus daclatasvir
subcutaneous casirivimab plus imdevimab
Timing of surgery
Tixagevimab plus cilgavimab (Evusheld)
Venous thromboembolism (VTE) prophylaxis
COVID-19 Research Pipeline
Cochrane COVID-19 Study Register
As at 30 September 2022
Tweets by evidenceCOVID19
FILTERED BY > Hydroxychloroquine
Guidelines update, v41.1
15 July, 2021
Version 41.1 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of six new studies on disease-modifying treatments. Convalescent plasma - two new studies comparing convalescent plasma to usual care in 912 and 160 patients with moderate-critical COVID-19 (Bégin et al.), (Sekine et al.) Hydroxychloroquine - one new study comparing hydroxychloroquine to usual care...
Guidelines update, version 34.1
18 February, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Dutasteride - preprint publication status has been removed from the summary information...
Weekly Communique #30
5 November, 2020
WEEK IN REVIEW Bromhexine hydrochloride added to list of 'only in clinical trials' The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed two new trial results for bromhexine hydrochloride (commonly...
Weekly Communique #28
22 October, 2020
WEEK IN REVIEW SAVING LIVES SAFELY: New CPR flowcharts published today The Taskforce, in partnership with the Infection Control Expert Group (ICEG), has published new clinical flowcharts to guide clinicians...
Weekly Communique #25
1 October, 2020
WEEK IN REVIEW List of drugs not recommended for use outside of clinical trials continues to grow The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed new trial results for...
Weekly Communique #17
6 August, 2020
WEEK IN REVIEW 'Do not use': The Taskforce has strengthened its recommendation against the use of hydroxychloroquine as a treatment for COVID-19 This week the Taskforce upgraded the strength...
Coverage: Taskforce hydroxychloroquine recommendation
5 August, 2020
Science reporter for the The Age and Sydney Morning Herald, Liam Mannix spoke to Taskforce Executive Director, A/Prof Julian Elliott regarding the 'Do Not Use' recommendation for the...
Weekly Communique #16
30 July, 2020
Dear colleagues, On behalf of all members of the Taskforce, we would like to take this opportunity to acknowledge our Victorian colleagues caring for people with COVID-19 during...
Weekly Communique #15
23 July, 2020
WEEK IN REVIEW Rooming-in recommendation The Pregnancy and Perinatal Care Panel have made their third conditional recommendation. This week's concerns Rooming-in: For women with COVID-19 who have given birth,...
Weekly Communique #14
16 July, 2020
WEEK IN REVIEW This week we experienced a shift in the level of alert among the clinicians who form Australia's frontline healthcare response to COVID-19, particularly in Victoria....
Weekly Communique #13
9 July, 2020
WEEK IN REVIEW COVID-19 and breastfeeding Following last week's recommendation on mode of birth, the Taskforce has now made a conditional recommendation on breastfeeding. Breastfeeding is supported irrespective of...
Weekly Communique #10
18 June, 2020
WEEK IN REVIEW Dexamethasone and RECOVERY Trial Oxford University's media release detailing preliminary results from the dexamethasone arm of the RECOVERY Trial dominated international headlines. In response, the...
Weekly Communique #6
21 May, 2020
Dear Taskforce Members and Contributors, Welcome to our new look electronic communique. We hope to provide you with weekly updates in a simple and efficient format so should...
Weekly Communique #5
14 May, 2020
TASKFORCE UPDATE This week we welcomed the Australian and New Zealand Society for Geriatric Medicine as a new member of the Taskforce. Two new expert guideline panels have...